IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

Inclusion Criteria:

1. Age ≥18 years (or legal age as per local regulations) at the time of signinginformed consent

2. Signed and dated written informed consent (either by the patient or impartialwitness) in accordance with ICH Good Clinical Practice (GCP) and local legislationprior to admission to the trial

3. Male or female participants of non-childbearing potential. Male participants must beready and able to use highly effective methods of birth control per ICH M3 (R2) forat least 5 days following investigational medicinal product (IMP) administration.Women who are not of childbearing potential are considered those that fulfil atleast one or more of the following: aged 50 years or above and being naturallyamenorrhoeic for at least 1 year (amenorrhoea following cancer therapy or duringbreast-feeding does not rule out childbearing potential) OR have premature ovarianfailure confirmed by a gynaecologist OR have undergone bilateralsalpingo-oophorectomy OR have undergone hysterectomy OR are affected by Turnersyndrome OR have uterine agenesis

4. Onset of symptoms of myocardial ischaemia or myocardial infarct, according topatient report, within a duration of:

Part A: ≥3 h and ≤8 h prior to randomisation Part B: ≥1 h and ≤12 h prior to randomisation Further inclusion criteria apply.

Exclusion Criteria:

1. Women of childbearing potential

2. Patients presenting with cardiogenic shock defined as either systolic blood pressure (SBP) ≤90 mmHg persisting despite fluid challenge or inotropes/vasopressors use tomaintain SBP >90 mmHg.

3. Known history of Heart Failure (HF) (based on verbal medical history as reported bya trial participant or authorised representative)

4. Known history of myocardial infarct (MI) with the exception of the index event (based on verbal medical history as reported by a trial participant or authorisedrepresentative)

5. Previous coronary artery bypass grafting (CABG) (based on verbal medical history asreported by a trial participant or authorised representative) Further exclusioncriteria apply.